Zachary Skidmore
Senior Scientist
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (14)
Year:
2026
Feline oral squamous cell carcinoma (FOSCC) and human head and neck squamous cell carcinoma (HNSCC) are the 4th most common malignant neoplasms in cats and humans. Most cats are not treated due to the poor prognosis and die of their disease within a few months of diagnosis. In humans, despite surgery, radiation therapy, and chemotherapy, 1/3 of patients develop loco‐regional recurrence within 5 years. FOSCC has commonly been proposed as a model for HNSCC since FOSCC is a spontaneous model and exhibits similar biologic behaviour, treatment course, and outcome to the human disease. The objective of this study was to identify genetic similarities and differences with HNSCC, therapeutic targets, and possible causes of FOSCC through whole exome sequencing. Thirty‐six matched normal FOSCC tumours and three matched normal chronic gingivostomatitis lesions were sequenced with a previously validated custom Roche Nimblegen exome reagent, based on the Felis_catus_9.0 genome assembly, covering 35.7 Mb. The exome libraries were pooled and sequenced on the Illumina Novaseq6000 as 2 × 150 bp reads. The data was analysed with the McDonnell Genome Institute's (MGI) cancer informatics pipelines, namely the Genome Modelling System (GMS), which was adapted to the feline genome. TP53 harboured consequential variants in 71% of the FOSCC tumours and was the most commonly mutated gene. Consequential variants in TTN were seen in 18% tumours and consequential variants in FSIP2, LRP1B, RYR2 were seen 9% of tumours. Genes with highly recurrent copy number variants (CNVs) included CKDN2A, PTEN, and MYC . TMB was very low, 0–1.6 (mean 0.66). Six cats had a history of chronic gingivostomatitis for years before the diagnosis of FOSCC. Despite the low TMB, the genomic landscape of FOSCC parallels HPV‐negative HNSCC. Aside from TP53, recurrent small‐scale mutations in FOSCC were uncommon, but recurrent CNVs were common. FOSCC is a genetically and clinically heterogenous cancer. A multifactorial cause is suspected. Chronic gingivostomatitis, immunosuppression, and/or viral infection may be associated with FOSCC in young cats.
Year:
2026
Determining response to therapy for patients with pancreatic cancer can be challenging. We evaluated methods for assessing therapeutic response using cell-free DNA (cfDNA) in plasma from patients with metastatic pancreatic cancer in the CheckPAC trial (NCT02866383). Patients were evaluated before and after initiation of therapy using tumor-informed plasma whole-genome sequencing (WGMAF) and tumor-independent genome-wide cfDNA fragmentation profiles and repeat landscapes (ARTEMIS-DELFI). Using WGMAF, molecular responders had a median overall survival (OS) of 319 days compared to 126 days for nonresponders [hazard ratio (HR) = 0.29, 95% confidence interval (CI) = 0.11–0.79, P = 0.011]. For ARTEMIS-DELFI, patients with low scores after therapy initiation had longer median OS than patients with high scores (233 versus 172 days, HR = 0.12, 95% CI = 0.046–0.31, P < 0.0001). We validated ARTEMIS-DELFI in patients with pancreatic cancer in the PACTO trial (NCT02767557). These analyses suggest that noninvasive mutation and fragmentation-based cfDNA approaches can identify therapeutic response of individuals with pancreatic cancer.
Year:
2025
Regulating Hippo. A, Diagram of pathways that regulate Hippo signaling. Identified SMGs are shown in red; genes mutated in at least one non-hypermutated sample are shown in yellow; genes only mutated in the hypermutated sample (HL-513) are shown in orange. The gene mutation frequency across the cohort is shown as a percent. The pathways labeled in green indicate larger pathways not shown in this diagram. B, The total number and type of mutation observed are shown in the inset bar chart. C, Lolliplot of CDH5 ; mutations identified in the current study are shown on the top and COSMIC mutations found in lymphoid tissue on the bottom. D, Lolliplot of mutations identified at GNA13 ; mutations identified in the current study are shown on the top and COSMIC mutations found in lymphoid tissue on the bottom.
Year:
2025
The malignant Hodgkin and Reed Sternberg (HRS) cells of classical Hodgkin lymphoma (cHL) are scarce in affected lymph nodes, creating a challenge to detect driver somatic mutations. As an alternative to cell purification techniques, we hypothesized that ultra-deep exome sequencing would allow genomic study of HRS cells, thereby streamlining analysis and avoiding technical pitfalls. To test this, 31 cHL tumor/normal pairs were exome sequenced to approximately 1,000× median depth of coverage. An orthogonal error-corrected sequencing approach verified >95% of the discovered mutations. We identified mutations in genes novel to cHL including: CDH5 and PCDH7, novel stop gain mutations in IL4R , and a novel pattern of recurrent mutations in pathways regulating Hippo signaling. As a further application of our exome sequencing, we attempted to identify expressed somatic single-nucleotide variants (SNV) in single-nuclei RNA sequencing (snRNA-seq) data generated from a patient in our cohort. Our snRNA analysis identified a clear cluster of cells containing a somatic SNV identified in our deep exome data. This cluster has differentially expressed genes that are consistent with genes known to be dysregulated in HRS cells (e.g., PIM1 and PIM3 ). The cluster also contains cells with an expanded B-cell clonotype further supporting a malignant phenotype. This study provides proof-of-principle that ultra-deep exome sequencing can be utilized to identify recurrent mutations in HRS cells and demonstrates the feasibility of snRNA-seq in the context of cHL. These studies provide the foundation for the further analysis of genomic variants in large cohorts of patients with cHL. Significance: Our data demonstrate the utility of ultra-deep exome sequencing in uncovering somatic variants in Hodgkin lymphoma, creating new opportunities to define the genes that are recurrently mutated in this disease. We also show for the first time the successful application of snRNA-seq in Hodgkin lymphoma and describe the expression profile of a putative cluster of HRS cells in a single patient.
Year:
2025
Circulating cell-free DNA (cfDNA) assays for monitoring individuals with cancer typically rely on prior identification of tumor-specific mutations. Here, we develop a tumor-independent and mutation-independent approach (DELFI-tumor fraction, DELFI-TF) using low-coverage whole genome sequencing to determine the cfDNA tumor fraction and validate the method in two independent cohorts of patients with colorectal or lung cancer. DELFI-TF scores strongly correlate with circulating tumor DNA levels (ctDNA) (r = 0.90, p < 0.0001, Pearson correlation) even in cases where mutations are undetectable. DELFI-TF scores prior to therapy initiation are associated with clinical response and are independent predictors of overall survival (HR = 9.84, 95% CI = 1.72-56.10, p < 0.0001). Patients with lower DELFI-TF scores during treatment have longer overall survival (62.8 vs 29.1 months, HR = 3.12, 95% CI 1.62-6.00, p < 0.001) and the approach predicts clinical outcomes more accurately than imaging. These results demonstrate the potential of using cfDNA fragmentomes to estimate tumor burden in cfDNA for treatment response monitoring and clinical outcome prediction.
Year:
2024
TAA expression analysis. A, TAA expression in a single simulation of a pancreatic adenocarcinoma clinical trial. Tumor associated antigen counts (MUC1 and Mesothelin for PAAD) are summarized for an example trial simulation in pancreatic adenocarcinoma. TAAs were assessed for each patient after taking into account the MHC alleles for either patient only (lysate-based analysis) or patient and vaccine (cell-based analysis), requiring evidence for both presentation of TAA peptide and robust expression of the TAA gene (Methods). B, TAA expression in each of five cancer types. For each cancer type, select established TAA genes were considered (Gp100, Ny-ESO-1 and MART-1 for SKCM; VEGFR1 and Ny-ESO-1 for LUAD; VEGFR1 and Ny-ESO-1 for LUSC; PSA and PAP for PRAD). Counts of expressed TAAs across 300 patients for each tumor type are shown as violin plots with individual points representing the count for each simulated patient overlaid.
Year:
2024
Genome-wide germline variant and alloantigen analysis. A, Alloantigen analysis in a single simulation of a melanoma clinical trial. Nonspecific alloantigen presentation provided by allogeneic vaccines are quantified for each of 30 patients. Unique protein altering variants (teal) are shown along with those predicted to be strong binding (IC 50 B, Alloantigen analysis for five common cancer types, lysate and cell-based. The counts of predicted alloantigens corresponding to 10 simulated vaccine trials for five cancer types (300 simulated patients per cancer type) are depicted as violin plots for both a lysate-based (top) and cell-based (bottom) analysis.
Year:
2024
Shared neoantigen analysis in melanoma. A, Single Iteration of a simulated clinical trial using TCGA's melanoma (SKCM) cohort. The count of each patient's ( n = 30) protein-altering somatic variants and predicted neoantigens are shown in the top left panel. Quantification of each designated “vaccine” sample, both individually ( n = 3) and as a pooled “Vaccine” are provided in the top right panel. Shared variants and predicted neoantigens by cell-based and lysate-based analysis are shown in the bottom panel. B, Lysate-based neoantigen analysis of melanoma simulated clinical trial. Ten clinical trials in melanoma were simulated analyzing a total of 300 patients. The total number of shared neoantigens that each patient shared with the vaccine, by lysate-based analysis, is shown in the left. In patients who had one or more shared neoantigens with the vaccine, the identity and frequency of each neoantigen is shown in the right. C, Cell-based neoantigen analysis of melanoma simulated clinical trial. Ten clinical trials in melanoma were simulated analyzing a total of 300 patients. The total number of shared neoantigens that each patient shared with the vaccine, by cell-based analysis, is shown in the left. In patients who had one or more shared neoantigens with the vaccine, the identity and frequency of each neoantigen is shown in the right.
Year:
2024
Simulated clinical trial work flow and shared neoantigen analysis. Using cancer-type matched cohorts from the TCGA, 33 samples were selected randomly and designated as either “vaccine” ( n = 3) or “patient” ( n = 30). Analysis was then performed to determine the number of shared tumor-specific neoantigens between the pooled vaccine and each patient individually. Right, a neoantigen analysis workflow is depicted. Tumor-specific neoantigens were determined for each sample individually in the following order. All somatic variants in the tumor were first identified. Non–protein-altering variants were excluded. The total pool of possible peptides was then calculated, and those that did not result in a predicted neoantigen with an IC 50
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Collaborators (15)
Robert Fulton
Assistant Professor
Washington University in St. Louis
Todd A. Fehniger
Professor
Washington University School of Medicine
Obi Griffith
Professor
Washington University in St. Louis
Kilannin Krysiak
Associate Professor
Washington University in St. Louis
Nancy Bartlett
Koman Professor of Medical Oncology in Medicine
Washington University in St. Louis
Julia Johansen
Professor
Copenhagen University Hospital
Shirley Chu
University of Missouri
David A. Russler-Germain
Washington University School of Medicine
Santiago Peralta
Associate Professor
Cornell University
Eric J. Duncavage
Professor/Director of Molecular Oncology
Washington University School of Medicine
Malachi Griffith
Professor
Washington University in St. Louis
Christopher Miller
Associate Professor
Washington University in St. Louis
Felicia Gomez
Assistant Professor (tenure track)
Washington University in St. Louis
Dae Young Kim
University of Missouri
Neha Mehta-Shah
Washington University School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.